Boyer N, Marcellin P, Degott C, Degos F, Saimot A G, Erlinger S, Benhamou J P
Service d'Hépatologie, Hôpital Beaujon, Clichy, France.
J Infect Dis. 1992 Apr;165(4):723-6. doi: 10.1093/infdis/165.4.723.
To assess the response to and tolerance of recombinant interferon-alpha administration in patients with chronic hepatitis C and human immunodeficiency virus (HIV) infection, 12 patients with chronic hepatitis C and HIV infection were given interferon-alpha, 1, 3, or 5 million units thrice weekly, for 4 or 6 months. Four patients had a complete response (normal serum alanine aminotransferase activity [ALT]), 3 had a near-complete response (serum ALT less than one-and-one-half times the upper limit of normal), and 5 had no response at the end of administration. Histologic examination of liver showed an improvement in 1 patient with complete response and no improvement in another patient with no response. In patients with chronic hepatitis C with HIV infection, the response to and tolerance of recombinant interferon-alpha were not different from those usually observed in patients with chronic hepatitis C infection without HIV infection.
为评估重组干扰素α对慢性丙型肝炎合并人类免疫缺陷病毒（HIV）感染患者的疗效及耐受性，12例慢性丙型肝炎合并HIV感染患者接受了干扰素α治疗，剂量为每周3次，每次100万、300万或500万单位，疗程4或6个月。4例患者获得完全缓解（血清丙氨酸氨基转移酶活性[ALT]正常），3例患者获得接近完全缓解（血清ALT低于正常上限的1.5倍），5例患者在治疗结束时无反应。肝脏组织学检查显示，1例获得完全缓解的患者肝脏有所改善，另1例无反应的患者则无改善。在慢性丙型肝炎合并HIV感染的患者中，重组干扰素α的疗效及耐受性与通常在无HIV感染的慢性丙型肝炎感染患者中观察到的情况无差异。
